The FDA outlined two complementary moves aimed at reshaping how studies start and how foreign trial data are scrutinized. First, the agency launched an Expedited Investigational New Drug (IND) Pilot under Operation Trialblazer, offering up to 10 qualified research institutions a path to rolling review for early IND components. At the same time, the FDA signaled tighter scrutiny of early-stage data coming from China, citing concerns about regulatory oversight capacity and the generalizability of results to US patients. The backdrop includes congressional attention on trial site conduct and the practical challenges the agency faces in auditing overseas clinical sites. Together, the steps suggest a faster route to first-in-human studies in the US, while increasing compliance pressure around how data generated abroad is trusted.